The Hematology Society of Taiwan yesterday said acute myeloid leukemia (AML), a fast-growing cancer of the blood and bone marrow, can progress quickly and aggressively and urged the government to ...
Precision Biologics, Inc. announces a new target in Acute Myeloid Leukemia (AML) for CAR-NK therapy. Recent data for several human AML subtypes expressing truncated core 1 O-glycans will be presented ...
MedPage Today on MSN
Big Jump in Therapy-Related AML Amid Growth in Population of Cancer Survivors
Study from Japan shows near-tripling over 30-year period ...
Know AML will mark AML World Awareness Day on Tuesday April 21, 2026, uniting patients, caregivers, societies, and the wider community to raise awareness of acute myeloid leukemia (AML). Many people ...
Leukemia is adept at dodging the immune system, making it resistant to many of the newest generation of cancer ...
A comprehensive approach is necessary for navigating the highly heterogeneous nature of leukemia across different age ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year survival below 30% ...
Orum's New Preclinical Data at AACR 2026 on ORM-1153 Highlights Broad Activity in AML and the Potential for Improved Efficacy ...
Acute myeloid leukemia (AML) has a poor prognosis, especially in elderly and relapsed/refractory patients, with 5‑year ...
Delta-Fly Pharma Inc. is pressing ahead with discussions with the FDA for its lead acute myeloid leukemia (AML) candidate, radgocitabine (DFP-10917), despite a phase III miss on its primary endpoint, ...
Researchers conducted a systematic review and meta-analysis for studies of acute myeloid leukemia patients with a median age less than 70 treated with HMA plus venetoclax.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results